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To compare the cost of two patient management strategies with similar efficacies for chronic
inflammatory demyelinating polyneuropathy (CIDP) patients in the chronic phase: hospital-
based IV immunoglobulin G (IVIg) and home-based subcutaneous immunoglobulin G
(SCIg) associated with an interprofessional drug therapy management programme (initial
training and follow-up).
Methods
A 48-week model-based cost-minimization analysis from a societal perspective was per-
formed. Resources included immunoglobulin (IVIg: 1 g/kg/3 weeks; SCIg: 0.4 g/kg/week ini-
tially and 0.2 g/kg/week in the maintenance phase), hospital charges, time of professionals,
infusion material, transport and losses of productivity for patients. Costs were expressed in
Swiss francs (CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28).
Results
The total costs of IVIg were higher than those of SCIg for health insurance and other payers:
114,747 CHF versus 86,558 CHF and 8,762 CHF versus 2,401 CHF, respectively. The
results were sensitive to the immunoglobulin doses, as this was the main cost driver. The
SCIg daily cost in the initial phase was higher for health insurance than hospital-based IVIg
was, but the additional costs were compensated during the maintenance phase (from week
28). The professional costs associated with the switch were not fully covered by the insur-
ance and were borne by the pharmacist and the nurse.
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Conclusions
SCIg for CIDP patients reinforced by an interprofessional drug therapy management pro-
gramme may be a cost-effective and sustainable alternative to IVIg in the Swiss system con-
text. From an economic perspective, this therapy alternative should be more widely
supported by healthcare systems and proposed to eligible patients by professionals.
1. Introduction
Home-based subcutaneous immunoglobulin G (SCIg) is well established in the treatment of
primary immunodeficiency diseases (PIDs) but is recent in neurology [1]. In Switzerland, only
Hizentra1 (CSL Behring) has been indicated since 2019 to treat chronic inflammatory demy-
elinating polyneuropathy (CIDP) in adults. CIDP patients generally receive hospital-based IV
immunoglobulin G (IVIg), and the switch to SCIg has not yet been systematically proposed.
The administration process is the same for PID and CIDP patients [2]. However, for CIDP
patients, SCIg is indicated only as maintenance treatment after IVIg stabilization.
For CIDP patients, SCIg is considered to lead to similar clinical outcomes than IVIg and is
well tolerated [3, 4]. SCIg is also often preferred by patients over IVIg, as it is associated to bet-
ter satisfaction and quality of life [5–7]. Previous studies have shown than SCIg has the poten-
tial to be cost-effective in different countries for both PID patients [8–14] and CIDP patients
[15–17]. The findings are sensitive to the national context, and more importantly, the cost of
patients training and follow-up is often overlooked. Indeed, in the long-term use of SCIg, pro-
fessionals stay responsible for optimal safety, effectiveness and proper medication adherence.
Therefore, an interprofessional drug therapy management programme has been proposed for
years by the Center for Primary Care and Public Health (Unisanté, Lausanne) to train patients
with SCIg and ensure a long-term support programme for them [18, 19].
The aim of this study is to compare the cost of hospital-based IVIg and home-based SCIg
associated with the patient support programme (Fig 1) to determine whether this alternative
should be promoted in the Swiss context. The model and findings are transposable to other
contexts adopting national unit costs.
2. Materials and methods
2.1 Study design
SCIg is indicated for CIDP patients as maintenance therapy after stabilization with IVIg. All
patients started IVIg treatment at the hospital. Resources related to the stabilization phase
were not estimated in this study because there is no alternative management treatment. The
study assumed a standard CIDP patient in the chronic phase who was eligible for SCIg (after
stabilization).
The following two management strategies were compared (Fig 1):
1. Hospital-based IVIg therapy (named “IVIg”) corresponding to the Lausanne University
hospital outpatient setting (CHUV, Lausanne, Switzerland),
2. Home-based SCIg therapy (named “SCIg”) associated with an interprofessional drug ther-
apy management programme during the initial phase (involving training sessions) and
maintenance phase (follow-up).
Both strategies were considered to provide identical effectiveness in the treatment of CIDP
in terms of relapse rates [3, 20]. We assessed the cost of the strategies over a 48-week period
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based on the main clinical study related to SCIg for CIDP patients [3, 4, 21] through a cost-
minimization analysis. We adopted a societal perspective, i.e., we considered all costs distin-
guishing the payers (healthcare insurers, patients, and community). As no data from real
patients were available, we adopted a simulation model whose data were mainly based on
product monographs, international guidelines and expert opinions.
2.2 Resource use and costs
The parameters considered are shown in Table 1. The results were expressed in Swiss francs
(CHF) (1 CHF = 0.93€ = US$1.10, www.xe.com, 2020/10/28).
2.3 Treatment
The theoretical standard patient was a 75 kg adult who was clinically stable to switch from
IVIg to SCIg. The infusion doses were estimated according to product monographs [2, 22].
The standard patient received over 48 weeks:
• In IVIg therapy, 1 g/kg body weight every three weeks, i.e., 75 g in total was spread over two
days in the hospital. We counted 16 infusion cycles over a 48-week period
• In SCIg therapy during the initial phase, 0.4 g/kg body weight every week, i.e., 30 g in total
by week, spread over two infusions of 15 g at home. We counted 48 infusions over a 24-week
period; then, during the maintenance phase, 0.2 g/kg every week, i.e., 15 g by infusion at
home. We counted 24 infusion cycles over a 24-week period (Fig 1).
The choice of IgG products corresponded to Hizentra1 (CSL Behring) for SCIg (the only
SCIg indicated in Switzerland to treat CIDP) and Privigen1 for IVIg (also manufactured by
CSL Behring and the cheapest IVIg in Switzerland, allowing a conservative approach in our
model). The costs of IgG corresponded to the public prices in the Swiss market [23] (see
Table 1). The cost per gram from the largest package available in the Swiss market is 69 CHF
for Hizentra1 and 75 CHF for Privigen1.
Fig 1. Decision tree for management of CIDP patients, stable in the chronic phase, treated by IgG infusions. a Interprofessional drug
therapy management programme as developed and implemented at the Community Pharmacy of the Center for Primary Care and Public
Health (Unisanté), University of Lausanne, Switzerland. b Duration included transport and time spent at patient’s home. c Duration included
transport ant time spent at hospital (infusions + waiting time + administrative time).
https://doi.org/10.1371/journal.pone.0242630.g001
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Table 1. Key model assumptions.
Parameters Base case Source
Patient’s characteristics
Patient’s weight 75 kg Experts’ opinion
Treatment—Hospital-based IVIg
Dose IgG–Maintenance phase 1 g/kg body weight/3 weeks [22]
Number of administrations (per 48 weeks) 16 (over 2 subsequent days) [22]
Cost IgG Privigen1 per package 2,987 CHF (40 g/400 mL) [23]
1,528 CHF (20 g/200 mL)
784 CHF (10 g/100 mL)
400 CHF (5 g/50 mL)
Patient timeb 4 h/infusion Experts’ opinion
Hospital charges per infusion 321 CHF/infusion [24]
Treatment—Home-based SCIg [2]
Dose IgG–Initial phase 0.4 g/kg body weight/week
Dose IgG–Maintenance phase 0.2 g/kg body weight/week
Number of administrations 48 per 48 weeks [2]
Cost IgG Hizentra1 per package 692 CHF (10 g/50 mL) [23]
287 CHF (4 g/20 mL)
152 CHF (2 g/10 mL)
84 CHF (1 g/5 mL)
Dispensation fees 3.25 per prescription form and 4.30 per medicine [25]
Materials–Home-based SCIg
Self-infusion pump 2,840 CHF [26]
Infusion disposables 85 CHF/infusion
Other disposables (phase) 135 CHF/24 week (initial) Unisanté
67 CHF/24 weeks (maintenance)
Drug therapy management programme for SCIg
The training phase
Nurse 4 ha/session (n = 3) Unisanté
Community pharmacist 4 ha/session (n = 3) + 30 min feedback
Patient 3 h/session (n = 3)
Fess-for-service (training by the pharmacist) 320 CHF [25]
Hourly fees for the nurse [27]
Evaluation and counselling 80 CHF/h
Examination and treatment 65 CHF/h
The follow-up phase
Nurse 3 ha/administration under supervision (n = 1) Unisanté
Pharmacist 3 ha/administration under supervision (n = 1)
1 h (feedback + regular contacts)
Patient 2 h/administration under supervision (n = 1)
Labour costs
Nurse 80 CHF/h [28]
Pharmacist 87 CHF/h
Patient 63 CHF/h [29]
Transport
Distance home/hospital 15 km Lausanne University hospital (CHUV)
Travel time per way 30 min
(Continued)
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The cost of hospital charges for IVIg infusions was estimated by the Swiss tariff system for
medical acts [24] They covered professional time, required material and hospital overheads.
The cost of material required for home-based SCIg included fixed costs (e.g., infusion
pump) and variable costs per infusion (including needles, infusion tubing, and syringes) [26].
We estimated the total cost for the amortization of the pump during the first 24 weeks in SCIg
(initial phase), and we assumed that the patient did not stop SCIg during this period. In reality,
if the patient stops before the end of the initial phase (i.e., before the amortization of the pur-
chase cost of the pump), it is possible to charge the use of the pump based on the daily rental
price. Both options (purchase and rental of the pump) are similar regarding their costs from
the insurer perspective. Indeed, the pump currently costs 2,840 CHF and is rented at a daily
price of 16.20 CHF; this means that if a patient rents a pump, it is fully paid and becomes his
or her belonging after 25 weeks, approximately the duration of the 24-week initial phase [26].
The annual cost of disposables (including alcohol wipes, hand sanitizer, gauze, tape, sharps
container, etc.) was estimated to be 73 CHF on average for PID patients at the Community
Pharmacy of Unisanté [13]. We adjusted this cost according to the higher dosage for CIDP
patients compared to PID patients (multiplying by four during the initial phase and by two
during the maintenance phase). We counted dispensation fees for the validation of prescrip-
tions by the community pharmacist for four dispensations over 48 weeks (one per trimester).
It covers the pharmacists’ basic cognitive services associated with the delivery of the medicines
(e.g., drug information, prescription/dosage/drug-drug interactions checks or patient records)
[25].
Systemic side effects of SCIg are considered similar to those of IVIg, although the frequency
and severity of SCIg are generally lower [17, 20]. As each individual dose administered by
SCIg is smaller than IVIg, a reduction in side effects is expected, which could reduce the total
cost. From a conservative perspective and without solid cost data, we assumed the same cost of
side effects management in both strategies and did not take into account this variable.
2.4 Drug therapy management programme to support patients with SCIg
The patient support programme costs included training sessions and follow-up delivered by
the community pharmacist and the nurse (see Fig 1 and Table 1). The number of training ses-
sions and administrations under supervision can vary based on the patients’ needs. The
administration process is the same for PID and CIDP patients. Hence, the standard case was
estimated through data collected from a cohort of PID patients followed at the Community
Pharmacy of Unisanté, who switched to home-based SCIg as part of the interprofessional pro-
gramme [13]. For the delivery of this programme, the nurse’s services were charged to the
patient and covered by health insurance under the pricing terms and conditions [27]. The
community pharmacist can charge a fee-for-service once per patient during the switch for the
training (320 CHF per patient covered by the health insurance) [25]. The potential costs not
covered by the insurance were estimated to be supported by the nurse and the pharmacist, and
Table 1. (Continued)
Parameters Base case Source
Cost per km 1 CHF [30]
CHF = Swiss francs, min = minutes.
a Duration including transport and time spent at patient’s home
b Duration including transport and time spent at hospital (infusions + waiting time + administrative time).
https://doi.org/10.1371/journal.pone.0242630.t001
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these were not charged to the patient. As for PID patients, we did not include additional physi-
cian time or medical follow-up consultation for the SCIg compared to IVIg, as the medical
care is considered the same for both of them [13].
2.5 Labour costs
The hourly labour costs for health professionals were derived from the salary scale for public
officials in the Canton of Vaud [28] which defined salary classes (ranging from 1 to 18) and
grades (ranging from 0 to 26) according to experience. This scale is applied both in Unisanté
and CHUV. The annual gross salary for a mid-career clinical professional corresponded to
class 11/grade 13 for a community pharmacist and class 10/grade 13 for a nurse. We assumed
that nurses had the same level and grade in both strategies. A multiplier coefficient (22%) was
applied to consider social security contributions and reflect the full cost to the employer.
Finally, the number of annual working hours corresponded to applicable normal working
hours at Unisanté and CHUV (41 hours 30 per week excluding holidays, absenteeism and
down time).
2.6 Transport
We estimated transport costs covered by the patient commuting to the hospital for IVIg infu-
sions and supported by the pharmacy and the nurse for training sessions requiring commuting
to the patient’s home. Based on our experience with PID patients at the Community Pharmacy
of Unisanté and after validation by the neurologists at CHUV for CIDP patients, we assumed
the standard patient’s home was located 15 kilometres from the hospital, which corresponded
to thirty minutes each way by car. Transport costs were estimated using an applicable compen-
sation system in the canton of Vaud [30].
2.7 Indirect costs
We assumed that the standard patient was employed. The cost of productivity loss for the
patient was estimated through the median gross salary per capita in Switzerland in 2016 [29]
taking into account the social security contributions. The number of annual working hours
corresponded to usual working hours in Switzerland (40 hours per week excluding holidays,
absenteeism and down time). The total time for the patient to be administered IVIg included
transport and time spent at the hospital (infusions, waiting and administrative time). In SCIg,
we included the costs for time lost by the patient during both training and follow-up sessions.
However, we assumed that infusions at home were self-administered outside of working hours
and that the patient was free to perform various activities compatible with infusions [31].
2.8 Sensitivity analysis
The robustness of the results was tested by univariate sensitivity analyses, varying the parame-
ters considered to have the greatest impact on the model output, i.e., parameters associated
with the treatment [13], with other things being equal. The IgG dose for IVIg varied with the
associated number of cycles, days and duration of infusions over 48 weeks, all other things
being equal, from minimal dose (0.5 g/kg/6 weeks, 8 cycles over 48 weeks, 1 day infusion of 2
hours) to maximal dose (2 g/kg/3 weeks, 16 cycles over 48 weeks, 2 day infusion of 4 hours)
[22]. These values were validated by expert neurologists and corresponded to real-life situa-
tions, as IgG doses for CIDP patients vary more than those for PID patients. The SCIg doses
remained the same during the two treatment phases, independent of the previous IVIg doses,
because these are the only ones recommended currently [2].
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3. Results
Table 2 presents the costs per patient according to management strategies and phases over 48
weeks. IgG costs were the major charges, representing between 86% and 89% of costs covered
by health insurance and between 79% and 87% of total costs. IVIg was the most expensive
strategy (114,747 CHF versus 86,558 CHF over 48 weeks for IVIg and SCIg, respectively). SCIg
was more expensive in the initial phase than in the maintenance phase, mainly due to the
higher administered dose (0.4 g/kg/week versus 0.2 g/kg/week). The SCIg daily cost in the ini-
tial phase was more expensive for health insurance than IVIg, but the additional cost was com-
pensated during the maintenance phase (from week 28). Over 48 weeks, the total savings
associated with the switch to home-based SCIg for health insurance was estimated to be 21,828
CHF per patient. The professional costs associated with SCIg (training and follow-up services)
were not fully covered by Swiss insurance and were borne by the pharmacist and the nurse
(1,200 CHF and 507 CHF, respectively). The results were sensitive to the IgG dose used in the
IVIg strategy (see Table 3).
4. Discussion
The study showed the potential cost-effectiveness of home-based SCIg associated with an
interprofessional drug therapy management programme supporting CIDP patients from
health insurance, patient and community perspectives in the Swiss healthcare context. IgG
cost was the major cost driver, and SCIg was not cost-effective for CIDP patients who received
IVIg with minimal IgG dose (see Table 3). However, a solution should be found in which
health insurers pay for the costs of pharmacists and nurses who are not currently covered.
Table 2. Cost estimations per patient (CHF, Swiss francs).
Strategy Hospital-based
IVIg
Home-based SCIg + programme a
(altogether)
Home-based SCIg programme� (detailed by phase)




Dose 1 g/kg/3 weeks 0.4 g/kg/week, 0.2 g/kg/week 0.4 g/kg/week 0.2 g/kg/week
Health insurance 105,985 85,561 57,823 27,737
IgG 91,185 75,300 49,806 25,494
Hospital charges 14,801 n/a n/a n/a
SCIg material n/a 9,133 7,036 2,098
Fees for nurse n/a 777 646 131
Fees for pharmacist n/a 350 335 15
Other payers 8,762 2,401 1,776 626
Patient 672 n/a n/a n/a
Pharmacist n/a 1,200 831 369
Nurse n/a 507 377 130
Community 8,090 695 569 126
Total costs 114,747 87,962 59,599 28,363
Daily cost covered by the health
insurance
315 (over 336 days) 255 (over 336 days) 344 (over 168 days) 165 (over 168 days)
Total daily cost 342 (over 336 days) 262 (over 336 days) 355 (over 168 days) 169 (over 168 days)
a Interprofessional drug therapy management programme.
All figures are rounded up to the nearest whole number.
n/a: not applicable.
https://doi.org/10.1371/journal.pone.0242630.t002
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In this study, we used the static current IVIg dose/frequency regimen approved by the Food
& Drug Administration and other health authorities applied in routine care in Europe for
maintenance phase [22]. In practice, there is inter- and intra-individual variability depending
on the patient’s needs, clinical response and the course of the disease. A clinical algorithm for
individualized IVIg dosing based on patient response has emerged in the literature [32, 33] but
is not yet systematically implemented in routine practice. Our cost estimations based on a
static model cover the majority of treatment schemes observed in the cohort study for patients
on stable long-term treatment [32]. These estimations could be used in a more dynamic way to
take into account possible treatment fluctuation for a patient over time and disease.
Two other cost-minimization studies compared hospital-based IVIg and home-based SCIg
for CIDP patients in Italy over one year. These results confirmed the cost advantage in favour
of SCIg, with the same IgG dose in both strategies, from a local health service [16] and from a
societal perspective [15]. A recent study from the United States showed a cost advantage over
three weeks for lower dose SCIg (0.2 g/kg/week) but not for higher dose SCIg (0.4 g/kg/week)
compared to IVIg (1 g/kg/week), primarily due to the higher cost per gram of Hizentra1 com-
pared with Gamunex-C1 (Grifols Therapeutics) [17]. In the Swiss context, a previous cost-
minimization analysis performed for PID patients, including the same interprofessional drug
therapy management programme, estimated the total savings from switching to SCIg at 9,630
CHF per patient over three years from the societal perspective. The same IgG doses were
assumed for both strategies [13].
The IgG product cost represented the main total cost driver, so any difference in its cost per
gram influences the advantage for either strategy (see Table 3). These costs can greatly vary
from one country to another. In Switzerland, the cost per gram for all available IgG products
in IV is always higher than in SC (cost per gram for the largest package [34]: Intratect1 = 76
Table 3. Univariate sensitivity analyses (other things being equal) (CHF, Swiss francs).




Home-based SCIg + programme a (altogether,
unchanged)
Dose 0.5 g/kg/6 weeks 2 g/kg/3 weeks Initial (0.4 g/kg/week) and maintenance (0.2 g/kg/
week) phases
Health insurance 26,747 206,544 85,561
IgG 24,897 182,370 75,300
Hospital charges 1,850 24,175 n/a
SCIg material n/a n/a 9,133
Fees for nurse n/a n/a 777
Fees for pharmacist n/a n/a 350
Other payers 2,190 12,806 2,401
Patient 168 672 n/a
Pharmacist n/a n/a 1,200
Nurse n/a n/a 507
Community 2,022 12,134 695
Total costs 28,938 219,351 87,962
Daily cost covered by the health insurance
(over 336 days)
80 615 255
Total daily cost (over 336 days) 86 653 262
a Interprofessional drug therapy management programme.
All figures are rounded up to the nearest whole number.
n/a = not applicable.
https://doi.org/10.1371/journal.pone.0242630.t003
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CHF, Kiovig1 = 77 CHF, Octagam1 = 78 CHF, Privigen1 = 75 CHF, in IV versus Cuvitru1
= 73 CHF, Gammanorm1 = 67 CHF, Hizentra1 = 69 CHF in SC) (1 CHF = 0.93€ = US$1.10,
www.xe.com, 2020/10/28), which is in favour of SCIg. This is also the case in Denmark, where
the difference is even larger (Privigen1 = 111€/g versus Hizentra1 = 77€/g) [35], but not in
France (40€ versus 45€) [36] or in Belgium (44€ versus 48€) [37]. In the US study, the cost per
gram of Gamunex-C1 was much lower than that of Hizentra1 (111€ versus 154€) [17]. These
prices are negotiated at the national level and can be a political lever to encourage the switch
or not. The IgG cost also depends on the doses and weight of the patient. In our analysis, we
assumed weekly IgG doses for SCIg recommended for a standard patient [3].
The choice of a cost-minimization analysis was consistent with the state of current knowl-
edge. As subcutaneous alternatives are new for CIDP treatment, we lack clinical and follow-up
data for CIDP patients switching to home-based SCIg. The phase 3 randomized controlled
trial PATH compared low-dose (0.2 g/kg/week) and high-dose (0.4 g/kg/week) SCIg to pla-
cebo with CIDP patients responding to IVIg [3]. No data are available on the direct compari-
sons between IVIg and SCIg. Moreover, the real-life data on the probability of stopping the
SCIg alternative are not available. Patients may stop due to relapse or local side effects. In the
PATH trial, the discontinuation rate of SCIg during the 24-week period was defined as the
proportion of patients who relapsed or were removed from the study for any other reason [3].
The discontinuation rate was 63% (n = 36/57) in the placebo group, 39% (n = 22/57) in the
low-dose group (0.2 g/kg/week) and 33% (n = 19/58) in the high-dose group (0.4 g/kg/week)
(p = 0.0007). Of all the patients, 6 withdrew consent because of issues with SCIg infusions
(mild local reactions, did not feel comfortable with the SCIg technique, no longer wanted to
participate because of a need to travel abroad). The support of healthcare professionals in the
training and follow-up of patient switching (e.g., the drug therapy management programme)
could reduce these withdrawals. In the case of relapse of a stable patient (0.2 g/kg/week), it is
recommended to return to a higher subcutaneous dose of 0.4 g/kg/week [4]. If the patient does
not respond or if a relapse occurs at this dose, it is recommended to return to IVIg with the ini-
tial dose before the switch to SCIg. In this case, the SCIg alternative is no longer recom-
mended. From an economic perspective, if the patient discontinues the SCIg before the 28
weeks after the switch, the setting up costs will be lost for the health insurance and liberal pro-
fessionals, with potential additional management costs of the withdrawal (e.g., relapse, medical
visits). In this case, the rental of the infusion pump in SCIg until this purchase is an ideal
option.
For many patients, the home setting is the preferable therapy option leading to more auton-
omy and flexibility in SCIg [38, 39] or IVIg [40], as long as training and follow-up by profes-
sionals are provided [41]. Moreover, in a pandemic situation, the home setting avoids bringing
chronic patients to the hospital for treatment. Most authors recommend presenting each
patient with the potential advantages and disadvantages of both alternatives with respect to
individual preferences and competencies [17, 19].
Our study did not investigate the cost-effectiveness of home-based IVIg, which is uncom-
mon in Switzerland but appears to be an acceptable efficient alternative in other countries
such as in France for patients with autoimmune neuropathies [40]. We considered that this
management strategy is more expensive than SCIg for the health insurers accounting avoided
hospital costs but a higher IgG cost and long-term costs associated to recurrent home-based
care. We assumed it as less advantageous for patients too, because they cannot carry out daily
activities during IV treatment compared to SCIg (i.e. same loss of productivity than in the hos-
pital, except for commuting to the hospital).
Some limitations need to be acknowledged. The simulation model estimating the results is
based on assumptions, and conditional parameter values. Future researches should consider
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experimental prospective studies with real data collection (such as dosage, efficacy, quality of
life, cost data). We adopted as much as possible a conservative approach related to the eco-
nomic aspects of SCIg to avoid conclusions that were too favourable.
5. Conclusions
The results of the simulation model support the promotion of the switch to home-based SCIg
in the Swiss system context with an example of a patient support program involving several
healthcare professionals. The final management strategy decision should be discussed between
the patient and the clinicians considering these economic aspects, as well as pharmacokinetics,
administration procedures, adverse events and patient characteristics and preferences. SCIg
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Writing – review & editing: Aline Bourdin, Alex Vicino, Thierry Kuntzer.
References
1. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al. A new taxonomy for
describing and defining adherence to medications. British journal of clinical pharmacology. 2012; 73
(5):691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x PMID: 22486599
2. Product monograph—Hizentra. July 2018. http://labeling.cslbehring.ca/PM/CA/Hizentra/EN/Hizentra-
Product-Monograph.pdf. Accessed 2020/04/09.
3. van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G et al. Subcutaneous immuno-
globulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a
randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Neurology. 2018; 17(1):35–46.
https://doi.org/10.1016/S1474-4422(17)30378-2 PMID: 29122523
4. van Schaik IN, Mielke O, Bril V, van Geloven N, Hartung HP, Lewis RA et al. Long-term safety and effi-
cacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. Neurology(R) neuroim-
munology & neuroinflammation. 2019; 6(5):e590. https://doi.org/10.1212/NXI.0000000000000590
PMID: 31355323
5. Hadden RD, Marreno F. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN:
improved tolerability and patient satisfaction. Ther Adv Neurol Disord. 2015; 8(1):14–9. https://doi.org/
10.1177/1756285614563056 PMID: 25584070
PLOS ONE Home-based subcutaneous immunoglobulin and cost-minimization analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0242630 November 25, 2020 10 / 12
6. Markvardsen LH, Harbo T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treat-
ment satisfaction and costs. Journal of the Neurological Sciences. 2017; 378:19–25. https://doi.org/10.
1016/j.jns.2017.04.039 PMID: 28566163
7. Gentile L, Mazzeo A, Russo M, Arimatea I, Vita G, Toscano A. Long-term treatment with subcutaneous
immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-
up period up to 7 years. Scientific reports. 2020; 10(1):7910. https://doi.org/10.1038/s41598-020-
64699-6 PMID: 32404895
8. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R et al. Subcutaneous immu-
noglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;
345(8946):365–9. https://doi.org/10.1016/s0140-6736(95)90346-1 PMID: 7845120
9. Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients
with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health
Econ. 2005; 6(1):24–9. https://doi.org/10.1007/s10198-004-0250-5 PMID: 15480920
10. Liu Z, Albon E, GHyde C, WMHTA C. The effectiveness and cost effectiveness of immunoglobulin
replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic
review and economic evaluation. University of Birmingham: Department of Public Health and
Epidemiology2005.
11. Beaute J, Levy P, Millet V, Debre M, Dudoit Y, Le Mignot L et al. Economic evaluation of immunoglobu-
lin replacement in patients with primary antibody deficiencies. Clinical and experimental immunology.
2010; 160(2):240–5. https://doi.org/10.1111/j.1365-2249.2009.04079.x PMID: 20041884
12. Martin A, Lavoie L, Goetghebeur M, Schellenberg R. Economic benefits of subcutaneous rapid push
versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency.
Transfusion medicine. 2013; 23(1):55–60. https://doi.org/10.1111/j.1365-3148.2012.01201.x PMID:
23167310
13. Perraudin C, Bourdin A, Spertini F, Berger J, Bugnon O. Switching Patients to Home-Based Subcutane-
ous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Pro-
gram. Journal of clinical immunology. 2016; 36(5):502–10. https://doi.org/10.1007/s10875-016-0288-z
PMID: 27139500
14. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous
immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody
deficiencies: systematic review and meta analysis. Journal of clinical immunology. 2012; 32(6):1180–
92. https://doi.org/10.1007/s10875-012-9720-1 PMID: 22730009
15. Lazzaro C, Lopiano L, Cocito D. Subcutaneous vs intravenous administration of immunoglobulin in
chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis. Neurological
sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neuro-
physiology. 2014; 35(7):1023–34. https://doi.org/10.1007/s10072-014-1632-9 PMID: 24469345
16. Cocito D, Serra G, Paolasso I, Barila DA, Lopiano L, Cattel L. Economic and quality of life evaluation of
different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. Journal of the
peripheral nervous system: JPNS. 2012; 17(4):426–8. https://doi.org/10.1111/j.1529-8027.2012.
00444.x PMID: 23279347
17. Allen JA, Gelinas DF, Freimer M, Runken MC, Wolfe GI. Immunoglobulin administration for the treat-
ment of CIDP: IVIG or SCIG? J Neurol Sci. 2019; 408:116497. https://doi.org/10.1016/j.jns.2019.
116497 PMID: 31765922
18. Bourdin A, Berger J, Bugnon O. Immunoglobulin self-infusion: an interprofessional drug therapy man-
agement program. 42nd European Symposium on Clinical Pharmacy symposium on Clinical Pharmacy:
Implementation of Pharmacy Practice; 16–18 October 2013; Prague, Czech Republic: International
Journal of Clinical Pharmacy; 2013. p. 1281–2.
19. Bourdin A, Berger J, Fruh A, Spertini F, Bugnon O. [Subcutaneous immunoglobulin and support pro-
gram: what level of interest of patients?]. Revue medicale suisse. 2015; 11(469):831–5. PMID:
26040165
20. Racosta JM, Sposato LA, Kimpinski K. Subcutaneous versus intravenous immunoglobulin for chronic
autoimmune neuropathies: A meta-analysis. Muscle & nerve. 2017; 55(6):802–9. https://doi.org/10.
1002/mus.25409 PMID: 27649063
21. van Schaik IN, van Geloven N, Bril V, Hartung HP, Lewis RA, Sobue G et al. Subcutaneous immuno-
globulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH
Study): study protocol for a randomized controlled trial. Trials. 2016; 17(1):345. https://doi.org/10.1186/
s13063-016-1466-2 PMID: 27455854
22. Product monograph—Privigen. 2019. http://labeling.cslbehring.ca/PM/CA/Privigen/EN/Privigen-
Product-Monograph.pdf. Accessed 2020/04/09.
PLOS ONE Home-based subcutaneous immunoglobulin and cost-minimization analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0242630 November 25, 2020 11 / 12
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